A Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06F

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-525213-31-00

Enrollment

Registered

2026-05-12

Start date

Unknown

Completion date

Unknown

Last updated

2026-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal squamous cell carcinoma

Brief summary

Objective response rate (ORR)

Detailed description

Duration of response (DOR), Progression-free survival (PFS), Overall survival (OS), Number of participants who experience an adverse event (AE), Number of participants who discontinue study intervention due to an AE

Interventions

DRUGIfinatamab Deruxtecan

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Objective response rate (ORR)	—

Secondary

Measure	Time frame
Duration of response (DOR), Progression-free survival (PFS), Overall survival (OS), Number of participants who experience an adverse event (AE), Number of participants who discontinue study intervention due to an AE	—

Outcome results

None listed

Source: EU CTIS · Data processed: May 13, 2026